Page last updated: 2024-11-08

dichamanetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

dichamanetin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID181193
CHEMBL ID1835968
CHEBI ID69681
SCHEMBL ID13708484
MeSH IDM0500906

Synonyms (14)

Synonym
dichamanetin
(2s)-5,7-dihydroxy-6,8-bis[(2-hydroxyphenyl)methyl]-2-phenyl-2,3-dihydrochromen-4-one
4h-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-6,8-bis((2-hydroxyphenyl)methyl)-2-phenyl-, (s)-
58779-09-2
chebi:69681 ,
CHEMBL1835968
SCHEMBL13708484
DTXSID90207506
bdbm50079360
AKOS030552820
(2s)-5,7-dihydroxy-6,8-bis[(2-hydroxyphenyl)methyl]-2-phenyl-3,4-dihydro-2h-1-benzopyran-4-one
(s)-5,7-dihydroxy-6,8-bis(2-hydroxybenzyl)-2-phenylchroman-4-one
compound np-021303
Q27138022

Research Excerpts

Overview

Dichamanetin is a C-benzylated flavanone isolated as a major secondary metabolite from Piper sarmentosum, a plant used as a spice.

ExcerptReferenceRelevance
"Dichamanetin is a C-benzylated flavanone isolated as a major secondary metabolite from Piper sarmentosum, a plant used as a spice in Southeast Asia. "( Dichamanetin inhibits cancer cell growth by affecting ROS-related signaling components through mitochondrial-mediated apoptosis.
DE Blanco, EJ; Kinghorn, AD; Matthew, S; Pan, L; Shen, Q; Swanson, SM; Wittwer, J; Yong, Y, 2013
)
3.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
diarylheptanoidA family of plant metabolites with a common 1,7-diphenylheptane structural skeleton, carrying various substituents. They are mainly distributed in the roots, rhizomes and bark of Alpinia, Zingiber, Curcuma and Alnus species.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cell division protein FtsZEscherichia coli K-12IC50 (µMol)12.50005.81007.556710.0000AID1201462
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
protein polymerizationCell division protein FtsZEscherichia coli K-12
cell divisionCell division protein FtsZEscherichia coli K-12
division septum assemblyCell division protein FtsZEscherichia coli K-12
FtsZ-dependent cytokinesisCell division protein FtsZEscherichia coli K-12
protein polymerizationCell division protein FtsZEscherichia coli K-12
cell divisionCell division protein FtsZEscherichia coli K-12
cell septum assemblyCell division protein FtsZEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
GTPase activityCell division protein FtsZEscherichia coli K-12
protein bindingCell division protein FtsZEscherichia coli K-12
GTP bindingCell division protein FtsZEscherichia coli K-12
identical protein bindingCell division protein FtsZEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytoplasmCell division protein FtsZEscherichia coli K-12
cell division siteCell division protein FtsZEscherichia coli K-12
plasma membraneCell division protein FtsZEscherichia coli K-12
divisome complexCell division protein FtsZEscherichia coli K-12
cytoplasmCell division protein FtsZEscherichia coli K-12
cell division siteCell division protein FtsZEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID623566Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Bioassay-guided isolation of constituents of Piper sarmentosum using a mitochondrial transmembrane potential assay.
AID1201467Antimicrobial activity against Bacillus subtilis2015European journal of medicinal chemistry, May-05, Volume: 95Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ.
AID623565Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Bioassay-guided isolation of constituents of Piper sarmentosum using a mitochondrial transmembrane potential assay.
AID1625186Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 200 ug/mL using p-nitrophenyl alpha-D-glucoside as substrate by colorimetric assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
α-Glucosidase Inhibitory Flavonoids and Oxepinones from the Leaf and Twig Extracts of Desmos cochinchinensis.
AID1201462Inhibition of Escherichia coli FtsZ GTPase activity2015European journal of medicinal chemistry, May-05, Volume: 95Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ.
AID1648006Cytotoxicity against HEK293 cells assessed as growth inhibition at 40 uM relative to control2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID1201469Antimicrobial activity against Staphylococcus aureus2015European journal of medicinal chemistry, May-05, Volume: 95Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ.
AID1625187Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl alpha-D-glucoside as substrate by colorimetric assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
α-Glucosidase Inhibitory Flavonoids and Oxepinones from the Leaf and Twig Extracts of Desmos cochinchinensis.
AID1648003Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as reduction in parasite rowth incubated for 72 hrs by DAPI staining based fluorescence assay2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID1648004Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as reduction in parasite growth incubated for 72 hrs by DAPI staining based fluorescence assay2020Journal of natural products, 02-28, Volume: 83, Issue:2
A Meroisoprenoid, Heptenolides, and
AID623567Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Bioassay-guided isolation of constituents of Piper sarmentosum using a mitochondrial transmembrane potential assay.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]